Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition

KalVista Pharmaceuticals brings to Chiesi Group the product Ekterly, the first FDA-approved oral drug for acute treatment of swelling attacks from the rare disease hereditary angioedema. Ekterly’s tablet formulation offers a dosing edge compared to injectable HAE medications. The post Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition appeared first on MedCity…

Read More

A Closer Look at Rural Nursing Homes

This analysis compares the characteristics of nursing homes in rural areas with those in urban areas. This brief uses data from Nursing Home Compare, a publicly available dataset that provides a snapshot of information on quality of care in each nursing home.

Read More

AI-Driven Layoffs In Healthcare: Navigating Legal Risks and Operational Challenges

Layoffs tied to AI adoption will not be uniform; they will vary by sector, job function, and regulatory exposure. Nowhere is this more complex than in healthcare, where legal constraints, patient safety obligations, and labor dynamics intersect with rapid technological change. The post AI-Driven Layoffs In Healthcare: Navigating Legal Risks and Operational Challenges appeared first…

Read More